{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:28:16Z","timestamp":1790368096768,"version":"4.1.0"},"reference-count":40,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2023,8,22]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Progressive pulmonary fibrosis (PPF) includes any diagnosis of progressive fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). However, disease progression appears comparable between PPF and IPF, suggesting a similar underlying pathology relating to pulmonary fibrosis. Following positive results in a phase II study in IPF, this phase III study will investigate the efficacy and safety of BI 1015550 in patients with PPF (FIBRONEER-ILD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>In this phase III, double-blind, placebo-controlled trial, patients are being randomised 1:1:1 to receive BI 1015550 (9 mg or 18\u2009mg) or placebo twice daily over at least 52 weeks, stratified by background nintedanib use. Patients must be diagnosed with pulmonary fibrosis other than IPF that is progressive, based on predefined criteria. Patients must have forced vital capacity (FVC) \u226545% predicted and haemoglobin-corrected diffusing capacity of the lung for carbon monoxide \u226525% predicted. Patients must be receiving nintedanib for at least 12 weeks, or not receiving nintedanib for at least 8 weeks, prior to screening. Patients on stable treatment with permitted immunosuppressives (eg, methotrexate, azathioprine) may continue their treatment throughout the trial. Patients with clinically significant airway obstruction or other pulmonary abnormalities, and those using immunosuppressives that may confound FVC results (cyclophosphamide, tocilizumab, mycophenolate, rituximab) or high-dose steroids will be excluded. The primary endpoint is absolute change from baseline in FVC (mL) at week 52. The key secondary endpoint is time to the first occurrence of any acute ILD exacerbation, hospitalisation for respiratory cause or death, over the duration of the trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The trial is being carried out in accordance with the ethical principles of the Declaration of Helsinki, the International Council on Harmonisation Guideline for Good Clinical Practice and other local ethics committees. The study results will be disseminated at scientific congresses and in peer-reviewed publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05321082\">NCT05321082<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2022-001580","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T22:25:12Z","timestamp":1694730312000},"page":"e001580","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct05321082","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05321069","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05321082","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-9149","authenticated-orcid":false,"given":"Toby M","family":"Maher","sequence":"first","affiliation":[{"name":"Department of Pulmonary, Critical Care and Sleep Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA"},{"name":"Section of Inflammation, Repair and Development, Imperial College London National Heart and Lung Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shervin","family":"Assassi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of Texas McGovern Medical School, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0506-9966","authenticated-orcid":false,"given":"Arata","family":"Azuma","sequence":"additional","affiliation":[{"name":"Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan"},{"name":"Respiratory Medicine and Clinical Research Centre, Meisei Hospital, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[{"name":"Service de pneumologie, H\u00f4pital Louis Pradel, Centre de R\u00e9f\u00e9rence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, Universit\u00e9 Claude Bernard Lyon 1, iNRAE, member of ERN-LUNG, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[{"name":"Center for Interstitial and Rare Lung Diseases, Department of Pneumology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M","family":"Oldham","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8594-1448","authenticated-orcid":false,"given":"Luca","family":"Richeldi","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa Complessa di Pneumologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0856-6290","authenticated-orcid":false,"given":"Claudia","family":"Valenzuela","sequence":"additional","affiliation":[{"name":"ILD Unit, Pulmonology Department, Hospital Universitario de la Princesa, University Autonomade Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies S","family":"Wijsenbeek","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Coeck","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim SComm, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Schlecker","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Voss","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wachtlin","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cornell University, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"2025083111081297000_10.1.e001580.1","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0076-2018","article-title":"Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Cottin","year":"2018","journal-title":"Eur Respir Rev"},{"key":"2025083111081297000_10.1.e001580.2","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0074-2018","article-title":"Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence","volume":"27","author":"Richeldi","year":"2018","journal-title":"Eur Respir Rev"},{"key":"2025083111081297000_10.1.e001580.3","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1007\/s12325-022-02145-x","article-title":"Meta-analysis of effect of nintedanib on reducing FVC decline across interstitial lung diseases","volume":"39","author":"Bonella","year":"2022","journal-title":"Adv Ther"},{"key":"2025083111081297000_10.1.e001580.4","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases. Reply","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N Engl J Med"},{"key":"2025083111081297000_10.1.e001580.5","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-1296-3"},{"key":"2025083111081297000_10.1.e001580.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2025083111081297000_10.1.e001580.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2025083111081297000_10.1.e001580.8","doi-asserted-by":"crossref","first-page":"2000085","DOI":"10.1183\/13993003.00085-2020","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"56","author":"Brown","year":"2020","journal-title":"Eur Respir J"},{"key":"2025083111081297000_10.1.e001580.9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ebiom.2019.10.050","article-title":"Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease","volume":"50","author":"Hoffmann-Vold","year":"2019","journal-title":"EBioMedicine"},{"key":"2025083111081297000_10.1.e001580.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2025083111081297000_10.1.e001580.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2025083111081297000_10.1.e001580.12","first-page":"1596","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease. reply","volume":"381","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"2025083111081297000_10.1.e001580.13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00259","article-title":"Inhaled phosphodiesterase 4 (PDE4) inhibitors for inflammatory respiratory diseases","volume":"11","author":"Phillips","year":"2020","journal-title":"Front Pharmacol"},{"key":"2025083111081297000_10.1.e001580.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2008.00041.x"},{"key":"2025083111081297000_10.1.e001580.15","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13753","article-title":"Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury","volume":"6","author":"Sisson","year":"2018","journal-title":"Physiol Rep"},{"key":"2025083111081297000_10.1.e001580.16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.838449","article-title":"BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis","volume":"13","author":"Herrmann","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025083111081297000_10.1.e001580.17","doi-asserted-by":"crossref","DOI":"10.1016\/S0165-6147(02)02089-8","article-title":"4D or not 4D \u2013 the emetogenic basis of PDE4 inhibitors uncovered","volume":"23","author":"Giembycz","year":"2002","journal-title":"Trends Pharmacol Sci"},{"key":"2025083111081297000_10.1.e001580.18","first-page":"762","article-title":"Trial of a phosphodiesterase 4 inhibitor for idiopathic pulmonary fibrosis. reply","volume":"387","author":"Richeldi","year":"2022","journal-title":"N Engl J Med"},{"key":"2025083111081297000_10.1.e001580.19","unstructured":"Boehringer Ingelheim International GmbH . Ofev (Nintedanib) capsules, for oral use. 2022. Available: https:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Ofev\/ofev.pdf [Accessed 24 Nov 2022]."},{"key":"2025083111081297000_10.1.e001580.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2017-000212","article-title":"Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease","volume":"4","author":"Flaherty","year":"2017","journal-title":"BMJ Open Respir Res"},{"key":"2025083111081297000_10.1.e001580.21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(22)01052-2","article-title":"Interstitial lung diseases","volume":"400","author":"Wijsenbeek","year":"2022","journal-title":"Lancet"},{"key":"2025083111081297000_10.1.e001580.22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2B trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2025083111081297000_10.1.e001580.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.069518"},{"key":"2025083111081297000_10.1.e001580.24","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2025083111081297000_10.1.e001580.25","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025083111081297000_10.1.e001580.26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2021-001026","article-title":"Phase 2 trial design of BMS-986278, a Lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive Fibrotic interstitial lung disease (PF-ILD)","volume":"8","author":"Corte","year":"2021","journal-title":"BMJ Open Respir Res"},{"key":"2025083111081297000_10.1.e001580.27","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"2025083111081297000_10.1.e001580.28","doi-asserted-by":"crossref","unstructured":"Richeldi L , Azuma A , Cottin V , et al . Late Breaking Abstract - Additive effect of BI 1015550 and nintedanib in patients with IPF (OA1396). Barcelona, Spain: European Respiratory Society, 2022.","DOI":"10.1183\/13993003.congress-2022.4606"},{"key":"2025083111081297000_10.1.e001580.29","unstructured":"Boehringer Ingelheim International GmbH . A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally; 2019."},{"key":"2025083111081297000_10.1.e001580.30","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201506-1063ST"},{"key":"2025083111081297000_10.1.e001580.31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/17460441.2016.1184642","article-title":"The discovery of Roflumilast for the treatment of chronic obstructive pulmonary disease","volume":"11","author":"Cazzola","year":"2016","journal-title":"Expert Opin Drug Discov"},{"key":"2025083111081297000_10.1.e001580.32","unstructured":"European Medicines Agency . Otezla\u00ae (Apremilast): summary of product characteristics. 2022. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/otezla-epar-product-information_en.pdf [Accessed 02 Aug 2022]."},{"key":"2025083111081297000_10.1.e001580.33","unstructured":"U.S. Food & Drug Administration . OTEZLA\u00ae (Apremilast): prescribing information. 2021. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/205437s011lbl.pdf [Accessed 23 Feb 2022]."},{"key":"2025083111081297000_10.1.e001580.34","unstructured":"U.S. Food & Drug Administration . DALIRESP\u00ae (Roflumilast): prescribing information. 2018. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/022522s009lbl.pdf [Accessed 28 Jan 2022]."},{"key":"2025083111081297000_10.1.e001580.35","unstructured":"European Medicines Agency . Daxas\u00ae (Roflumilast): summary of product characteristics. 2022. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/daxas-epar-product-information_en.pdf [Accessed 02 Aug 2022]."},{"key":"2025083111081297000_10.1.e001580.36","doi-asserted-by":"publisher","DOI":"10.1080\/01926230500385549"},{"key":"2025083111081297000_10.1.e001580.37","unstructured":"U.S. Food & Drug Administration . Roflumilast: tertiary pharmacology review. 2009. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022522Orig1s000PharmR.pdf [Accessed 02 Aug 2022]."},{"key":"2025083111081297000_10.1.e001580.38","unstructured":"European Medicines Agency . Summary of risk management plan for Otezla\u00ae (Apremilast). 2022. Available: https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/otezla-epar-risk-management-plan-summary_en.pdf [Accessed 02 Aug 2022]."},{"key":"2025083111081297000_10.1.e001580.39","unstructured":"U.S. Food & Drug Administration . Apremilast: tertiary pharmacology review. 2014. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205437Orig1s000PharmR.pdf [Accessed 02 Aug 2022]."},{"key":"2025083111081297000_10.1.e001580.40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001563","article-title":"Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)","volume":"10","author":"Richeldi","year":"2023","journal-title":"BMJ Open Respir Res"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2022-001580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T18:08:28Z","timestamp":1756663708000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2022-001580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,9,14]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/bmjresp-2022-001580"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2022-001580","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}